Thalidomide for the treatment of angiodysplasia-related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?
Harish K PatelShehriyar MehershahiDanial Haris ShaikhJasbir MakkerSuresh Kumar NayuduProspere RemySridhar ChilimuriPublished in: Clinical case reports (2019)
Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose-dependent. The low-dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.